Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656530 | 1.00 | POLB (1.00) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11878483 | 0.99 | POLB (0.97) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2677556 | 0.94 | POLB (0.89) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11876757 | 0.90 | POLB (0.81) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11875339 | 0.90 | POLB (0.81) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13593334 | 0.89 | POLB (0.80) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5655969 | 0.89 | POLB (0.80) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20339052 | 0.89 | KMT2A (0.88) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3207873 | 0.88 | SMN1; SMN2 (0.79) | POLBMAPK1SMN1; SMN2KMT2AMEN1 | |
| Capobenic Acid SCHEMBL123463 | 0.86 | KMT2A (0.79) | POLBMAPK1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1025 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2018-05-10 | — | — | US | claimed |
| US-9622969-B2 | Polymer conjugated protein micelles | SOUTH DAKOTA STATE UNIV (US) | 2017-04-18 | — | — | US | claimed |
| CN-106431952-A | Synthetic method of capobenic acid intermediate epsilon-(3, 4, 5-trimethoxybenzoylamino]acetic acid | 厦门安普顿信息科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | claimed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | POLB 3497/4885MAPK1 3559/4885SMN1; SMN2 2075/4885 |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, NOS3 | POLB 2092/4885MAPK1 2228/4885SMN1; SMN2 1489/4885 |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | POLB 4572/4885MAPK1 4143/4885SMN1; SMN2 4125/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | POLB 3497/4885MAPK1 3559/4885SMN1; SMN2 2075/4885 |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | OGFR, HDGF, SERPINA6 | POLB 1984/4885MAPK1 1716/4885SMN1; SMN2 4612/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | POLB 2585/4885MAPK1 3828/4885SMN1; SMN2 1968/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | POLB 4452/4885MAPK1 4044/4885SMN1; SMN2 1924/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | POLB 1968/4885MAPK1 2412/4885SMN1; SMN2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.